SK11362000A3 - Spôsob zlepšenia sexuálnej dysfunkcie žien - Google Patents

Spôsob zlepšenia sexuálnej dysfunkcie žien Download PDF

Info

Publication number: SK11362000A3
Authority: SK; Slovakia
Prior art keywords: apomorphine; women; blood flow; cyclodextrin; administered
Prior art date: 1998-01-30

Application number

SK1136-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ragab El-Rashidy

Bruce Ronsen

Original Assignee

Pentech Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-30

Filing date

1999-01-28

Publication date

2001-02-12

1999-01-28 Application filed by Pentech Pharmaceuticals, Inc. filed Critical Pentech Pharmaceuticals, Inc.

2001-02-12 Publication of SK11362000A3 publication Critical patent/SK11362000A3/sk

Links

206010057671 Female sexual dysfunction Diseases 0.000 title claims description 12
229960004046 apomorphine Drugs 0.000 claims abstract description 84
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims abstract description 84
230000017531 blood circulation Effects 0.000 claims abstract description 37
230000036470 plasma concentration Effects 0.000 claims abstract description 9
201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 7
231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 7
230000001568 sexual effect Effects 0.000 claims description 21
238000000034 method Methods 0.000 claims description 17
210000003029 clitoris Anatomy 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 14
229920000858 Cyclodextrin Polymers 0.000 claims description 13
238000009472 formulation Methods 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 10
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
239000001116 FEMA 4028 Substances 0.000 claims description 8
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
229960004853 betadex Drugs 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
206010028813 Nausea Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
230000008693 nausea Effects 0.000 claims description 7
230000000638 stimulation Effects 0.000 claims description 7
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 6
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 4
210000004556 brain Anatomy 0.000 claims description 4
102000015554 Dopamine receptor Human genes 0.000 claims description 3
108050004812 Dopamine receptor Proteins 0.000 claims description 3
230000036770 blood supply Effects 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
230000006698 induction Effects 0.000 claims 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 18
210000005036 nerve Anatomy 0.000 abstract description 10
230000001668 ameliorated effect Effects 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 15
229960003990 apomorphine hydrochloride Drugs 0.000 description 15
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
238000001990 intravenous administration Methods 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000003826 tablet Substances 0.000 description 10
210000001215 vagina Anatomy 0.000 description 10
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
230000007383 nerve stimulation Effects 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
229930195725 Mannitol Natural products 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
229960005070 ascorbic acid Drugs 0.000 description 7
235000010323 ascorbic acid Nutrition 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
235000010355 mannitol Nutrition 0.000 description 7
239000000594 mannitol Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
230000000982 vasogenic effect Effects 0.000 description 6
230000002411 adverse Effects 0.000 description 5
230000004872 arterial blood pressure Effects 0.000 description 5
238000005461 lubrication Methods 0.000 description 5
239000006190 sub-lingual tablet Substances 0.000 description 5
108010011485 Aspartame Proteins 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000000605 aspartame Substances 0.000 description 4
235000010357 aspartame Nutrition 0.000 description 4
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
229960003438 aspartame Drugs 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
229920003084 Avicel® PH-102 Polymers 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920003102 Methocel™ E4M Polymers 0.000 description 3
230000037007 arousal Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229960001253 domperidone Drugs 0.000 description 3
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
230000001856 erectile effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000011587 new zealand white rabbit Methods 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
230000001107 psychogenic effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 2
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000002111 antiemetic agent Substances 0.000 description 2
229940125683 antiemetic agent Drugs 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000004882 diastolic arterial blood pressure Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
239000002895 emetic Substances 0.000 description 2
-1 for example Chemical compound 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
201000001881 impotence Diseases 0.000 description 2
230000018052 penile erection Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
GRZMOSSVIPFGFF-GNJLJDPWSA-N 2-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 GRZMOSSVIPFGFF-GNJLJDPWSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 description 1
229940098778 Dopamine receptor agonist Drugs 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
SDBHDSZKNVDKNU-UHFFFAOYSA-N buclizine dihydrochloride Chemical compound Cl.Cl.C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 SDBHDSZKNVDKNU-UHFFFAOYSA-N 0.000 description 1
229960001676 buclizine hydrochloride Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960001677 cyclizine hydrochloride Drugs 0.000 description 1
UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
229960004993 dimenhydrinate Drugs 0.000 description 1
229960005058 diphenidol hydrochloride Drugs 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940099182 dramamine Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000001257 erectogenic effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000009245 menopause Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
229960000767 metopimazine Drugs 0.000 description 1
BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
229940078646 other antiemetics in atc Drugs 0.000 description 1
229950005217 oxypendyl Drugs 0.000 description 1
RUPOLIZWSDDWNJ-UHFFFAOYSA-N oxypendyl Chemical compound C1CN(CCO)CCN1CCCN1C2=NC=CC=C2SC2=CC=CC=C21 RUPOLIZWSDDWNJ-UHFFFAOYSA-N 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
210000002640 perineum Anatomy 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 description 1
229950008580 pipamazine Drugs 0.000 description 1
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
229960003111 prochlorperazine Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940098466 sublingual tablet Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000004873 systolic arterial blood pressure Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000006439 vascular pathology Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940072018 zofran Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1136-2000A 1998-01-30 1999-01-28 Spôsob zlepšenia sexuálnej dysfunkcie žien SK11362000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/016,252 US5945117A (en)	1998-01-30	1998-01-30	Treatment of female sexual dysfunction
PCT/US1999/001776 WO1999038467A1 (en)	1998-01-30	1999-01-28	Treatment of female sexual dysfunction

Publications (1)

Publication Number	Publication Date
SK11362000A3 true SK11362000A3 (sk)	2001-02-12

Family

ID=21776169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1136-2000A SK11362000A3 (sk)	1998-01-30	1999-01-28	Spôsob zlepšenia sexuálnej dysfunkcie žien

Country Status (34)

Country	Link
US (2)	US5945117A (pl)
EP (1)	EP1056419A4 (pl)
JP (1)	JP2002501875A (pl)
KR (1)	KR20010040477A (pl)
CN (1)	CN1250221C (pl)
AR (1)	AR017976A1 (pl)
AU (1)	AU752928B2 (pl)
BG (1)	BG64667B1 (pl)
BR (1)	BR9908038A (pl)
CA (1)	CA2322289A1 (pl)
CO (1)	CO4970819A1 (pl)
CR (1)	CR5959A (pl)
DZ (1)	DZ2714A1 (pl)
GC (1)	GC0000096A (pl)
GT (1)	GT199900013A (pl)
HK (1)	HK1040901B (pl)
HN (1)	HN1999000015A (pl)
HU (1)	HUP0101268A3 (pl)
IL (2)	IL137569A0 (pl)
JO (1)	JO2085B1 (pl)
MA (1)	MA26600A1 (pl)
MX (1)	MXPA00007447A (pl)
NO (1)	NO319821B1 (pl)
NZ (1)	NZ506597A (pl)
PA (1)	PA8467801A1 (pl)
PE (1)	PE20000240A1 (pl)
PL (1)	PL194350B1 (pl)
SK (1)	SK11362000A3 (pl)
TN (1)	TNSN99008A1 (pl)
TR (1)	TR200002220T2 (pl)
TW (1)	TW550069B (pl)
UY (1)	UY25374A1 (pl)
WO (1)	WO1999038467A1 (pl)
ZA (1)	ZA99686B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395744B1 (en) *	1994-04-22	2002-05-28	Queen's University At Kingston	Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) *	1994-04-22	2002-11-07	Heaton Jeremy P. W.	Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) *	1996-02-02	2005-03-24	Nitromed, Inc.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en)	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
US5945117A (en) *	1998-01-30	1999-08-31	Pentech Pharmaceuticals, Inc.	Treatment of female sexual dysfunction
AU2003204720B2 (en) *	1998-05-29	2006-06-29	Tap Pharmaceutical Products Inc.	Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO1999066909A2 (en) *	1998-06-22	1999-12-29	Univ Kingston	Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) *	1999-07-01	2005-11-03	40 J's Llc	Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) *	1999-11-08	2004-12-16	Pfizer Inc	Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) *	2000-03-20	2001-10-16	Abbott Lab	Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
MXPA02009904A (es) *	2000-04-07	2004-09-06	Tap Pharmaceutical Prod Inc	Derivados de apomorfina y metodos para su uso.
DE60131644T2 (de) *	2000-05-09	2008-10-30	Nitromed, Inc., Lexington	Infrarotthermographie und behandlung von sexuellen dysfunktionen
US6737084B2 (en)	2000-06-27	2004-05-18	Qualilife	Compositions and methods for enhancing or treating female sexual response
US7223406B2 (en)	2000-07-21	2007-05-29	The Regents Of The University Of California	Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) *	2000-07-21	2003-12-03	Lue, Tom	Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) *	2000-08-21	2002-05-30	Davies Michael John	Treatment of wounds
PL361875A1 (pl)	2000-11-15	2004-10-04	Tap Pharmaceutical Products, Inc.	Sposób leczenia zaburzeń czynności seksualnych wywołanych lekami przeciwdepresyjnymi z zastosowaniem apomorfiny
PL365890A1 (pl) *	2000-11-22	2005-01-10	Abbott Laboratories	Zastosowanie selektywnych agonistów receptorów dopaminowych D4 w leczeniu dysfunkcji seksualnej
EP1365740A1 (en) *	2001-02-08	2003-12-03	Pharmacia Corporation	Rapid-onset medicament for the treatment of sexual dysfunction
CA2479372A1 (en) *	2002-03-19	2003-10-02	Michael Holick	Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20030219696A1 (en) *	2002-05-23	2003-11-27	Moreland Gerald W.	Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
GB0221711D0 (en) *	2002-09-19	2002-10-30	Ardana Bioscience Ltd	Methods
US20040138291A1 (en) *	2002-10-10	2004-07-15	Adams Michael A.	Treatment of sexual dysfunction
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) *	2003-04-14	2004-10-14	Staniforth John Nicholas	Composition, device, and method for treating sexual dysfunction via inhalation
CA2522231A1 (en) *	2003-04-14	2004-10-21	Vectura Ltd	Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US7306812B2 (en)	2003-05-09	2007-12-11	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) *	2003-05-09	2007-10-02	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) *	2003-06-17	2003-07-23	Pfizer Ltd	Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) *	2003-08-08	2005-03-10	Pfizer Inc	Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) *	2003-08-20	2005-03-24	Lts Lohmann Therapie-Systeme Ag	Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) *	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) *	2004-04-30	2004-06-09	Pfizer Ltd	Novel compounds
JP4185154B2 (ja) *	2004-04-30	2008-11-26	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	中枢神経系障害治療用の置換モルホリン化合物
US20080214622A1 (en) *	2005-03-21	2008-09-04	Alan Daniel Brown	Substituted Triazole Derivatives As Oxytocin Antagonists
EP1863795B1 (en) *	2005-03-21	2008-10-29	Pfizer Limited	Substituted triazole derivatives as oxytocin antagonists
RU2406480C2 (ru) *	2005-04-08	2010-12-20	Озфарма Пти Лтд	Трансбуккальная система доставки
JP2009504628A (ja) *	2005-08-10	2009-02-05	ファイザー・リミテッド	オキシトシン拮抗薬としての置換トリアゾール誘導体
EP2010505B1 (en) *	2006-03-28	2012-12-05	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) *	2007-06-11	2010-09-21	Macronix International Co., Ltd.	Resistance memory with tungsten compound and manufacturing
ES2699077T3 (es)	2009-06-12	2019-02-07	Sunovion Pharmaceuticals Inc	Apomorfina sublingual
WO2011130608A1 (en) *	2010-04-15	2011-10-20	Life Science Enhancement Corporation	Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
PT2651357T (pt)	2010-12-16	2020-06-17	Sunovion Pharmaceuticals Inc	Películas sublinguais
EP2697206B1 (en)	2011-04-10	2019-04-03	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en)	2011-07-11	2013-01-16	Britannia Pharmaceuticals Limited	A new therapeutical composition containing apomorphine as active ingredient
EP4578461A3 (en)	2015-04-21	2025-09-03	Sumitomo Pharma America, Inc.	Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4521421A (en) *	1983-09-26	1985-06-04	Eli Lilly And Company	Treatment of sexual dysfunction
EP0641202A1 (en) *	1992-05-18	1995-03-08	Smithkline Beecham Plc	Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) *	1993-08-13	1996-10-15	Zonagen, Inc.	Methods for modulating the human sexual response
WO1995028930A1 (en) *	1994-04-22	1995-11-02	Pentech Pharmaceuticals, Inc.	Dosage forms and method for ameliorating male erectile dysfunction
US5562917A (en) *	1994-12-23	1996-10-08	Pentech Pharmaceuticals, Inc.	Transdermal administration of apomorphine
US5624677A (en) *	1995-06-13	1997-04-29	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) *	1998-01-30	1999-08-31	Pentech Pharmaceuticals, Inc.	Treatment of female sexual dysfunction

1998
- 1998-01-30 US US09/016,252 patent/US5945117A/en not_active Expired - Fee Related
1999
- 1999-01-21 TN TNTNSN99008A patent/TNSN99008A1/fr unknown
- 1999-01-28 CN CNB998044423A patent/CN1250221C/zh not_active Expired - Fee Related
- 1999-01-28 SK SK1136-2000A patent/SK11362000A3/sk unknown
- 1999-01-28 BR BR9908038-9A patent/BR9908038A/pt not_active Application Discontinuation
- 1999-01-28 KR KR1020007008333A patent/KR20010040477A/ko not_active Ceased
- 1999-01-28 HK HK02101988.0A patent/HK1040901B/zh not_active IP Right Cessation
- 1999-01-28 IL IL13756999A patent/IL137569A0/xx active IP Right Grant
- 1999-01-28 CA CA002322289A patent/CA2322289A1/en not_active Abandoned
- 1999-01-28 PL PL99342062A patent/PL194350B1/pl unknown
- 1999-01-28 AU AU25644/99A patent/AU752928B2/en not_active Ceased
- 1999-01-28 JP JP2000529203A patent/JP2002501875A/ja not_active Withdrawn
- 1999-01-28 HN HN1999000015A patent/HN1999000015A/es unknown
- 1999-01-28 TR TR2000/02220T patent/TR200002220T2/xx unknown
- 1999-01-28 NZ NZ506597A patent/NZ506597A/en unknown
- 1999-01-28 HU HU0101268A patent/HUP0101268A3/hu unknown
- 1999-01-28 ZA ZA9900686A patent/ZA99686B/xx unknown
- 1999-01-28 EP EP99905497A patent/EP1056419A4/en not_active Withdrawn
- 1999-01-28 CR CR5959A patent/CR5959A/es not_active Application Discontinuation
- 1999-01-28 MX MXPA00007447A patent/MXPA00007447A/es not_active IP Right Cessation
- 1999-01-28 JO JO19992085A patent/JO2085B1/en active
- 1999-01-28 WO PCT/US1999/001776 patent/WO1999038467A1/en not_active Ceased
- 1999-01-29 PA PA19998467801A patent/PA8467801A1/es unknown
- 1999-01-29 CO CO99005067A patent/CO4970819A1/es unknown
- 1999-01-29 UY UY25374A patent/UY25374A1/es not_active Application Discontinuation
- 1999-01-29 MA MA25442A patent/MA26600A1/fr unknown
- 1999-01-29 TW TW088101384A patent/TW550069B/zh not_active IP Right Cessation
- 1999-01-29 AR ARP990100389A patent/AR017976A1/es not_active Application Discontinuation
- 1999-01-29 PE PE1999000067A patent/PE20000240A1/es not_active Application Discontinuation
- 1999-01-30 DZ DZ990015A patent/DZ2714A1/xx active
- 1999-01-31 GC GCP199973 patent/GC0000096A/xx active
- 1999-07-02 US US09/345,009 patent/US6193992B1/en not_active Expired - Fee Related
2000
- 2000-07-27 IL IL137569A patent/IL137569A/en unknown
- 2000-07-27 NO NO20003845A patent/NO319821B1/no unknown
- 2000-08-28 BG BG104715A patent/BG64667B1/bg unknown
2001
- 2001-07-20 GT GT199900013A patent/GT199900013A/es unknown

Also Published As

Publication number	Publication date
NO20003845L (no)	2000-09-28
KR20010040477A (ko)	2001-05-15
NO319821B1 (no)	2005-09-19
TNSN99008A1 (fr)	2005-11-10
PA8467801A1 (es)	2000-09-29
GT199900013A (es)	2001-07-20
TW550069B (en)	2003-09-01
DZ2714A1 (fr)	2003-09-01
UY25374A1 (es)	1999-09-27
IL137569A (en)	2006-08-01
HUP0101268A3 (en)	2002-12-28
IL137569A0 (en)	2001-07-24
EP1056419A4 (en)	2007-05-02
MA26600A1 (fr)	2004-12-20
PL342062A1 (en)	2001-05-21
NZ506597A (en)	2003-07-25
TR200002220T2 (tr)	2000-12-21
CR5959A (es)	1999-07-28
BR9908038A (pt)	2002-01-02
AR017976A1 (es)	2001-10-24
ZA99686B (en)	1999-07-28
GC0000096A (en)	2005-06-29
JO2085B1 (en)	2000-05-21
HN1999000015A (es)	1999-08-23
US5945117A (en)	1999-08-31
WO1999038467A1 (en)	1999-08-05
AU2564499A (en)	1999-08-16
CN1250221C (zh)	2006-04-12
HK1040901B (zh)	2006-11-24
BG104715A (bg)	2001-02-28
PL194350B1 (pl)	2007-05-31
NO20003845D0 (no)	2000-07-27
EP1056419A1 (en)	2000-12-06
AU752928B2 (en)	2002-10-03
HUP0101268A2 (hu)	2001-09-28
BG64667B1 (bg)	2005-11-30
CA2322289A1 (en)	1999-08-05
CN1313742A (zh)	2001-09-19
PE20000240A1 (es)	2000-03-31
HK1040901A1 (en)	2002-06-28
MXPA00007447A (es)	2006-01-25
JP2002501875A (ja)	2002-01-22
CO4970819A1 (es)	2000-11-07
US6193992B1 (en)	2001-02-27

Publication	Publication Date	Title
US5945117A (en)	1999-08-31	Treatment of female sexual dysfunction
ES2244418T3 (es)	2005-12-16	Composiciones de apomorfina y sidenalfilo y utilizacion de los mismos para el tratamiento de la disfuncion erectil.
US6395744B1 (en)	2002-05-28	Method and compositions for the treatment or amelioration of female sexual dysfunction
EP0758895B1 (en)	2000-01-26	Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
KR20010101241A (ko)	2001-11-14	남성의 기질적 발기 부전 치료용 약제의 제조시아포모르핀의 용도
AU749703B2 (en)	2002-07-04	Combination therapy for modulating the human sexual response
US20040101484A1 (en)	2004-05-27	Nasal delivery of apomorphine in combination with glycol derivatives
JP2002518435A (ja)	2002-06-25	女性の性機能不全の治療または改善のための方法および組成物
CZ20002755A3 (cs)	2000-12-13	Způsob zlepšení ženské sexuální dysfunkce
MXPA01006105A (es)	2002-05-09	Uso de apomorfina en la elaboracion de un medicamento para el tratamiento de la disfuncion erectil organica en los hombres
HK1014239B (en)	2001-02-09	Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
HK1025742B (en)	2006-10-13	Sublingual composition containing apomorphine for diagnosing functional impotence